Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment

Worapol Ngamcherdtrakul, David J. Castro, Shenda Gu, Jingga Morry, Moataz Reda, Joe Gray, Wassana Yantasee

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

This Review discusses the various types of non-coding oligonucleotides, which have garnered extensive interest as new alternatives for targeted cancer therapies over small molecule inhibitors and monoclonal antibodies. These oligonucleotides can target any hallmark of cancer, no longer limited to so-called "druggable" targets. Thus, any identified gene that plays a key role in cancer progression or drug resistance can be exploited with oligonucleotides. Among them, small-interfering RNAs (siRNAs) are frequently utilized for gene silencing due to the robust and well established mechanism of RNA interference. Despite promising advantages, clinical translation of siRNAs is hindered by the lack of effective delivery platforms. This Review provides general criteria and consideration of nanoparticle development for systemic siRNA delivery. Different classes of nanoparticle candidates for siRNA delivery are discussed, and the progress in clinical trials for systemic cancer treatment is reviewed. Lastly, this Review presents HER2 (human epidermal growth factor receptor type 2)-positive breast cancer as one example that could benefit significantly from siRNA technology. How siRNA-based therapeutics can overcome cancer resistance to such therapies is discussed.

Original languageEnglish (US)
Pages (from-to)19-29
Number of pages11
JournalCancer Treatment Reviews
Volume45
DOIs
StatePublished - Apr 1 2016

Fingerprint

Oligonucleotides
Small Interfering RNA
Breast Neoplasms
Neoplasms
Nanoparticles
Therapeutics
Gene Silencing
RNA Interference
Drug Resistance
Monoclonal Antibodies
Clinical Trials
Technology
Genes

Keywords

  • Breast cancer
  • Nanoparticle
  • Oligonucleotide
  • SiRNA
  • Targeted delivery
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Current development of targeted oligonucleotide-based cancer therapies : Perspective on HER2-positive breast cancer treatment. / Ngamcherdtrakul, Worapol; Castro, David J.; Gu, Shenda; Morry, Jingga; Reda, Moataz; Gray, Joe; Yantasee, Wassana.

In: Cancer Treatment Reviews, Vol. 45, 01.04.2016, p. 19-29.

Research output: Contribution to journalArticle

Ngamcherdtrakul, Worapol ; Castro, David J. ; Gu, Shenda ; Morry, Jingga ; Reda, Moataz ; Gray, Joe ; Yantasee, Wassana. / Current development of targeted oligonucleotide-based cancer therapies : Perspective on HER2-positive breast cancer treatment. In: Cancer Treatment Reviews. 2016 ; Vol. 45. pp. 19-29.
@article{2cb695e8c00141d8aa7ea74053728a8a,
title = "Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment",
abstract = "This Review discusses the various types of non-coding oligonucleotides, which have garnered extensive interest as new alternatives for targeted cancer therapies over small molecule inhibitors and monoclonal antibodies. These oligonucleotides can target any hallmark of cancer, no longer limited to so-called {"}druggable{"} targets. Thus, any identified gene that plays a key role in cancer progression or drug resistance can be exploited with oligonucleotides. Among them, small-interfering RNAs (siRNAs) are frequently utilized for gene silencing due to the robust and well established mechanism of RNA interference. Despite promising advantages, clinical translation of siRNAs is hindered by the lack of effective delivery platforms. This Review provides general criteria and consideration of nanoparticle development for systemic siRNA delivery. Different classes of nanoparticle candidates for siRNA delivery are discussed, and the progress in clinical trials for systemic cancer treatment is reviewed. Lastly, this Review presents HER2 (human epidermal growth factor receptor type 2)-positive breast cancer as one example that could benefit significantly from siRNA technology. How siRNA-based therapeutics can overcome cancer resistance to such therapies is discussed.",
keywords = "Breast cancer, Nanoparticle, Oligonucleotide, SiRNA, Targeted delivery, Targeted therapy",
author = "Worapol Ngamcherdtrakul and Castro, {David J.} and Shenda Gu and Jingga Morry and Moataz Reda and Joe Gray and Wassana Yantasee",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.ctrv.2016.02.005",
language = "English (US)",
volume = "45",
pages = "19--29",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Current development of targeted oligonucleotide-based cancer therapies

T2 - Perspective on HER2-positive breast cancer treatment

AU - Ngamcherdtrakul, Worapol

AU - Castro, David J.

AU - Gu, Shenda

AU - Morry, Jingga

AU - Reda, Moataz

AU - Gray, Joe

AU - Yantasee, Wassana

PY - 2016/4/1

Y1 - 2016/4/1

N2 - This Review discusses the various types of non-coding oligonucleotides, which have garnered extensive interest as new alternatives for targeted cancer therapies over small molecule inhibitors and monoclonal antibodies. These oligonucleotides can target any hallmark of cancer, no longer limited to so-called "druggable" targets. Thus, any identified gene that plays a key role in cancer progression or drug resistance can be exploited with oligonucleotides. Among them, small-interfering RNAs (siRNAs) are frequently utilized for gene silencing due to the robust and well established mechanism of RNA interference. Despite promising advantages, clinical translation of siRNAs is hindered by the lack of effective delivery platforms. This Review provides general criteria and consideration of nanoparticle development for systemic siRNA delivery. Different classes of nanoparticle candidates for siRNA delivery are discussed, and the progress in clinical trials for systemic cancer treatment is reviewed. Lastly, this Review presents HER2 (human epidermal growth factor receptor type 2)-positive breast cancer as one example that could benefit significantly from siRNA technology. How siRNA-based therapeutics can overcome cancer resistance to such therapies is discussed.

AB - This Review discusses the various types of non-coding oligonucleotides, which have garnered extensive interest as new alternatives for targeted cancer therapies over small molecule inhibitors and monoclonal antibodies. These oligonucleotides can target any hallmark of cancer, no longer limited to so-called "druggable" targets. Thus, any identified gene that plays a key role in cancer progression or drug resistance can be exploited with oligonucleotides. Among them, small-interfering RNAs (siRNAs) are frequently utilized for gene silencing due to the robust and well established mechanism of RNA interference. Despite promising advantages, clinical translation of siRNAs is hindered by the lack of effective delivery platforms. This Review provides general criteria and consideration of nanoparticle development for systemic siRNA delivery. Different classes of nanoparticle candidates for siRNA delivery are discussed, and the progress in clinical trials for systemic cancer treatment is reviewed. Lastly, this Review presents HER2 (human epidermal growth factor receptor type 2)-positive breast cancer as one example that could benefit significantly from siRNA technology. How siRNA-based therapeutics can overcome cancer resistance to such therapies is discussed.

KW - Breast cancer

KW - Nanoparticle

KW - Oligonucleotide

KW - SiRNA

KW - Targeted delivery

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84959251161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959251161&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2016.02.005

DO - 10.1016/j.ctrv.2016.02.005

M3 - Article

C2 - 26930249

AN - SCOPUS:84959251161

VL - 45

SP - 19

EP - 29

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -